Protein / target
Thyroid hormone receptor beta
Protein at a glance
Biological role
Sequence-specific double-stranded DNA binding
Strongest disease association
Glycogen storage disease due to glycogen branching enzyme deficiency
Therapeutic position
Established drug target
Research activity
Emerging research
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Nuclear hormone receptor that can act as a repressor or activator of transcription.
View complete UniProt function annotationHide complete annotation
Nuclear hormone receptor that can act as a repressor or activator of transcription. High affinity receptor for thyroid hormones, including triiodothyronine and thyroxine
Subcellular location
Domains and Gene Ontology detail (26)Hide
Domains & features
Gene Ontology
- Cchromatin
- Cnuclear body
- Cnucleoplasm
- Cnucleus
- CRNA polymerase II transcription regulator complex
- Fchromatin DNA binding
- FDNA binding
- FDNA-binding transcription factor activity
- FDNA-binding transcription factor activity, RNA polymerase II-specific
- Fenzyme binding
- Fnuclear receptor activity
- FRNA polymerase II cis-regulatory region sequence-specific DNA binding
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Nuclear receptor signalling
- ·nuclear receptor activity
- ·Nuclear Receptor transcription pathway
Transcriptional regulation
- ·Nuclear hormone receptor that can act as a repressor or activator of transcription. High…
- ·RNA polymerase II transcription regulator complex
- ·DNA-binding transcription factor activity
- ·DNA-binding transcription factor activity, RNA polymerase II-specific
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
8 medicines meet Open Targets' target-level approved-medicine definition; the 1 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Thyroid hormone receptor beta-1 agonist
Indicated for Non-alcoholic Fatty Liver Disease
Thyroid hormone receptor agonist
Thyroid hormone receptor agonist
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene THRB
Gene-level evidence surfaced through the gene THRBthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
10 compounds recorded · 8 approved · 2 in clinical development
View all recorded compounds (10)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Protein degraders — Emerging
View underlying tractability evidence (6)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 3 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Label change
Label change: RESMETIROM (NDA217785)
- Label change
Label change: RESMETIROM (NDA217785)
- Label change
Label change: RESMETIROM (NDA217785)
- Label change
Label change: RESMETIROM (NDA217785)
- Regulatory approval
Approval: Rezdiffra (EMA)
- Regulatory approval
Approval: Emcitate (EMA)
- New publicationThyroid hormone and the Liver.
- New publicationHepatic thyroid hormone receptor-β signalling: Mechanisms and recent advancements in the treatment of metabolic dysfunction-associated steatohepatitis.
- New publicationThyroid hormone receptor-β analogues for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).
- New publicationThe first MASH drug therapy on the horizon: Current perspectives of resmetirom.
- Regulatory approval
Approval: RESMETIROM (NDA217785)
- New publicationMulti-trait analysis characterizes the genetics of thyroid function and identifies causal associations with clinical implications.
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.
Research activity
Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.
Most cited
Recent
Europe PMC papers linked directly to this protein.
Related family literature
Papers about “Receptors, Thyroid Hormone” — a broader family this protein belongs to. Shown as context; not counted as papers specifically about this protein.
via Receptors, Thyroid Hormone
via Receptors, Thyroid Hormone
via Receptors, Thyroid Hormone
via Receptors, Thyroid Hormone
via Receptors, Thyroid Hormone
via Receptors, Thyroid Hormone
via Receptors, Thyroid Hormone
Europe PMC literature, reached through curated HGNC family membership. Membership is a taxonomic relationship — it does not imply this protein participates in every mechanism these papers discuss.